The content on this site is intended for healthcare professionals only
Dr Dung T. Le presents, at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.
Read the news article and watch the interview for more.
WCI's role in the prevention of tobacco related cancer among Beedi rolling women in India
Alternative livelihood training programme for rural women who are employed in the tobacco industry in India
Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC
Choosing Wisely in endometrial & cervix cancers: Medical therapy
ESMO 2024: Highlights and analysis
Immunotherapy resistance pathways investigated to tailor combination NSCLC therapy
Mutational-based treatment approach may significantly improve outcomes in pretreated patients with metastatic solid tumours
Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures
OncoAlert round up July 28th to August 3rd, 2023
